High prevalence of urine tampering in an office-based opioid treatment practice detected by evaluating the norbuprenorphine to buprenorphine ratio

Anthony J. Accurso, Joshua Lee, Jennifer McNeely

Research output: Contribution to journalArticle

Abstract

The prevalence of urine tampering within office-based opioid treatment (OBOT) is not currently known. This study was a cross-sectional analysis of an OBOT practice in New York City that experienced both a change in provider and a change in electronic medical record software. At that time, every patient in the practice received a urine drug test for “quantitative buprenorphine metabolites.” Methods Outcomes of the first three urine drug tests were tabulated and analyzed with specific attention to the frequency of buprenorphine-positive (bup +), norbuprenorphine-negative (norbup −) samples, a pattern consistent with urine tampering. Results On the first sample 6/33 (18%) of patients submitted bup +/norbup − samples, and an additional 3 patients submitted bup +/norbup − samples on subsequent urine tests. Retention to the end of the study period among patients with bup +/norbup − samples was 33%, while in those with bup +/norbup + samples it was 96%. A scatter plot of norbuprenorphine vs. buprenorphine levels estimated that a ratio of < 0.2 indicated tampering. Conclusion Testing for buprenorphine metabolites yields valuable clinical information. The prevalence of a result pattern consistent with tampering by “urine spiking,” the addition of unconsumed buprenorphine into the urine sample, may be higher than previous estimates. Previous lower cutoffs of the norbuprenorphine:buprenorphine metabolic ratio may miss a substantial proportion of these likely tampered samples.

Original languageEnglish (US)
Pages (from-to)62-67
Number of pages6
JournalJournal of Substance Abuse Treatment
Volume83
DOIs
StatePublished - Dec 1 2017

Fingerprint

Buprenorphine
Opioid Analgesics
Urine
Therapeutics
Electronic Health Records
norbuprenorphine
Pharmaceutical Preparations
Software
Cross-Sectional Studies

ASJC Scopus subject areas

  • Phychiatric Mental Health
  • Medicine (miscellaneous)
  • Clinical Psychology
  • Psychiatry and Mental health

Cite this

High prevalence of urine tampering in an office-based opioid treatment practice detected by evaluating the norbuprenorphine to buprenorphine ratio. / Accurso, Anthony J.; Lee, Joshua; McNeely, Jennifer.

In: Journal of Substance Abuse Treatment, Vol. 83, 01.12.2017, p. 62-67.

Research output: Contribution to journalArticle

@article{2acb9fe330bf4d12a3c5d1259f31df86,
title = "High prevalence of urine tampering in an office-based opioid treatment practice detected by evaluating the norbuprenorphine to buprenorphine ratio",
abstract = "The prevalence of urine tampering within office-based opioid treatment (OBOT) is not currently known. This study was a cross-sectional analysis of an OBOT practice in New York City that experienced both a change in provider and a change in electronic medical record software. At that time, every patient in the practice received a urine drug test for “quantitative buprenorphine metabolites.” Methods Outcomes of the first three urine drug tests were tabulated and analyzed with specific attention to the frequency of buprenorphine-positive (bup +), norbuprenorphine-negative (norbup −) samples, a pattern consistent with urine tampering. Results On the first sample 6/33 (18{\%}) of patients submitted bup +/norbup − samples, and an additional 3 patients submitted bup +/norbup − samples on subsequent urine tests. Retention to the end of the study period among patients with bup +/norbup − samples was 33{\%}, while in those with bup +/norbup + samples it was 96{\%}. A scatter plot of norbuprenorphine vs. buprenorphine levels estimated that a ratio of < 0.2 indicated tampering. Conclusion Testing for buprenorphine metabolites yields valuable clinical information. The prevalence of a result pattern consistent with tampering by “urine spiking,” the addition of unconsumed buprenorphine into the urine sample, may be higher than previous estimates. Previous lower cutoffs of the norbuprenorphine:buprenorphine metabolic ratio may miss a substantial proportion of these likely tampered samples.",
author = "Accurso, {Anthony J.} and Joshua Lee and Jennifer McNeely",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.jsat.2017.10.002",
language = "English (US)",
volume = "83",
pages = "62--67",
journal = "Journal of Substance Abuse Treatment",
issn = "0740-5472",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - High prevalence of urine tampering in an office-based opioid treatment practice detected by evaluating the norbuprenorphine to buprenorphine ratio

AU - Accurso, Anthony J.

AU - Lee, Joshua

AU - McNeely, Jennifer

PY - 2017/12/1

Y1 - 2017/12/1

N2 - The prevalence of urine tampering within office-based opioid treatment (OBOT) is not currently known. This study was a cross-sectional analysis of an OBOT practice in New York City that experienced both a change in provider and a change in electronic medical record software. At that time, every patient in the practice received a urine drug test for “quantitative buprenorphine metabolites.” Methods Outcomes of the first three urine drug tests were tabulated and analyzed with specific attention to the frequency of buprenorphine-positive (bup +), norbuprenorphine-negative (norbup −) samples, a pattern consistent with urine tampering. Results On the first sample 6/33 (18%) of patients submitted bup +/norbup − samples, and an additional 3 patients submitted bup +/norbup − samples on subsequent urine tests. Retention to the end of the study period among patients with bup +/norbup − samples was 33%, while in those with bup +/norbup + samples it was 96%. A scatter plot of norbuprenorphine vs. buprenorphine levels estimated that a ratio of < 0.2 indicated tampering. Conclusion Testing for buprenorphine metabolites yields valuable clinical information. The prevalence of a result pattern consistent with tampering by “urine spiking,” the addition of unconsumed buprenorphine into the urine sample, may be higher than previous estimates. Previous lower cutoffs of the norbuprenorphine:buprenorphine metabolic ratio may miss a substantial proportion of these likely tampered samples.

AB - The prevalence of urine tampering within office-based opioid treatment (OBOT) is not currently known. This study was a cross-sectional analysis of an OBOT practice in New York City that experienced both a change in provider and a change in electronic medical record software. At that time, every patient in the practice received a urine drug test for “quantitative buprenorphine metabolites.” Methods Outcomes of the first three urine drug tests were tabulated and analyzed with specific attention to the frequency of buprenorphine-positive (bup +), norbuprenorphine-negative (norbup −) samples, a pattern consistent with urine tampering. Results On the first sample 6/33 (18%) of patients submitted bup +/norbup − samples, and an additional 3 patients submitted bup +/norbup − samples on subsequent urine tests. Retention to the end of the study period among patients with bup +/norbup − samples was 33%, while in those with bup +/norbup + samples it was 96%. A scatter plot of norbuprenorphine vs. buprenorphine levels estimated that a ratio of < 0.2 indicated tampering. Conclusion Testing for buprenorphine metabolites yields valuable clinical information. The prevalence of a result pattern consistent with tampering by “urine spiking,” the addition of unconsumed buprenorphine into the urine sample, may be higher than previous estimates. Previous lower cutoffs of the norbuprenorphine:buprenorphine metabolic ratio may miss a substantial proportion of these likely tampered samples.

UR - http://www.scopus.com/inward/record.url?scp=85032011615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032011615&partnerID=8YFLogxK

U2 - 10.1016/j.jsat.2017.10.002

DO - 10.1016/j.jsat.2017.10.002

M3 - Article

C2 - 29129197

AN - SCOPUS:85032011615

VL - 83

SP - 62

EP - 67

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

SN - 0740-5472

ER -